BRPI0516602A - composto, e, composição farmacêutica - Google Patents
composto, e, composição farmacêuticaInfo
- Publication number
- BRPI0516602A BRPI0516602A BRPI0516602-0A BRPI0516602A BRPI0516602A BR PI0516602 A BRPI0516602 A BR PI0516602A BR PI0516602 A BRPI0516602 A BR PI0516602A BR PI0516602 A BRPI0516602 A BR PI0516602A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- migraine
- schizophrenia
- depression
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102100038352 Metabotropic glutamate receptor 3 Human genes 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 108010038445 metabotropic glutamate receptor 3 Proteins 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/41—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrogenolysis or reduction of carboxylic groups or functional derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61978904P | 2004-10-18 | 2004-10-18 | |
| PCT/US2005/036665 WO2006044454A1 (en) | 2004-10-18 | 2005-10-13 | 1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mglur3 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0516602A true BRPI0516602A (pt) | 2008-09-16 |
Family
ID=35787981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0516602-0A BRPI0516602A (pt) | 2004-10-18 | 2005-10-13 | composto, e, composição farmacêutica |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7868014B2 (enExample) |
| EP (1) | EP1805165B1 (enExample) |
| JP (1) | JP5188807B2 (enExample) |
| CN (1) | CN101094846A (enExample) |
| AT (1) | ATE452130T1 (enExample) |
| AU (1) | AU2005295860A1 (enExample) |
| BR (1) | BRPI0516602A (enExample) |
| CA (1) | CA2584422A1 (enExample) |
| DE (1) | DE602005018381D1 (enExample) |
| ES (1) | ES2336130T3 (enExample) |
| MX (1) | MX2007004661A (enExample) |
| WO (1) | WO2006044454A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1757582T3 (pl) | 2004-05-28 | 2016-04-29 | Mitsubishi Tanabe Pharma Corp | Aryloalkiloaminy i sposób ich wytwarzania |
| FR2928150A1 (fr) | 2008-02-29 | 2009-09-04 | Vetoquinol Sa Sa | Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens |
| WO2009131196A1 (ja) * | 2008-04-24 | 2009-10-29 | 武田薬品工業株式会社 | 置換ピロリジン誘導体およびその用途 |
| EP2145891A1 (en) | 2008-07-09 | 2010-01-20 | Vetoquinol S.A. | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
| TW201022233A (en) * | 2008-11-04 | 2010-06-16 | Organon Nv | (Pyrrolidin-2-yl)phenyl derivatives |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| JP6678672B2 (ja) * | 2014-12-11 | 2020-04-08 | ヤンセン ファーマシューティカ エヌ．ベー． | １，２，４−トリアゾロ［４，３−ａ］ピリジン化合物およびＭＧＬＵＲ２受容体の正のアロステリック調節因子としてのその使用 |
| CN113024412A (zh) * | 2021-03-23 | 2021-06-25 | 上海立科化学科技有限公司 | 2,4,6-三氯苯腈的制备方法 |
| CN114149297A (zh) * | 2021-12-07 | 2022-03-08 | 北京中医药大学 | 一种微波辅助的选择性芳基甲醛的绿色合成方法 |
| CN115368283A (zh) * | 2022-09-15 | 2022-11-22 | 丽水绿氟科技有限公司 | 一种手性结构或非手性结构的顺式-3-氟-4-羟基吡咯烷及其衍生物的制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5001125A (en) * | 1984-03-26 | 1991-03-19 | Janssen Pharmaceutica N.V. | Anti-virally active pyridazinamines |
| US4785119A (en) * | 1985-10-11 | 1988-11-15 | Tokyo Kasei Kogyo Co., Ltd. | 3-aminopyrrolidine compound and process for preparation thereof |
| UA41251C2 (uk) | 1990-01-04 | 2001-09-17 | Пфайзер, Інк. | Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі |
| US5332817A (en) * | 1990-01-04 | 1994-07-26 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles |
| US5232929A (en) * | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
| TW202432B (enExample) * | 1991-06-21 | 1993-03-21 | Pfizer | |
| WO1995029891A1 (en) * | 1994-04-28 | 1995-11-09 | Yamanouchi Pharmaceutical Co., Ltd. | N-(3-pyrrolidinyl)benzamide derivative |
| ES2079323B1 (es) * | 1994-06-21 | 1996-10-16 | Vita Invest Sa | Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes. |
| DE19524765A1 (de) * | 1995-07-07 | 1997-01-09 | Boehringer Mannheim Gmbh | Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| JP2001521484A (ja) | 1996-01-22 | 2001-11-06 | イーライ・リリー・アンド・カンパニー | 置換されたインダンのライブラリーを製造するための組み合わせ方法 |
| US6313127B1 (en) | 1996-02-02 | 2001-11-06 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
| US5891889A (en) * | 1996-04-03 | 1999-04-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| JP2001515839A (ja) * | 1997-07-18 | 2001-09-25 | ジョージタウン・ユニバーシティ | 二環式向代謝性グルタミン酸受容体リガンド |
| CA2297906A1 (en) | 1997-07-22 | 1999-02-04 | Bret Eugene Huff | Pharmaceutical compounds |
| US20010006972A1 (en) | 1998-04-21 | 2001-07-05 | Stephen A. Williams | Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome |
| WO1999064396A1 (en) * | 1998-06-09 | 1999-12-16 | Neurogen Corporation | Substituted 1-aryl-3-benzylaminopyrrolidine: dopamine receptor subtype specific ligands |
| AU2002342414A1 (en) | 2001-05-10 | 2002-11-25 | Aventis Pharma Deutschland Gmbh | Novel processes for the preparation of adenosine compounds and intermediates thereto |
| US7521062B2 (en) * | 2002-12-27 | 2009-04-21 | Novartis Vaccines & Diagnostics, Inc. | Thiosemicarbazones as anti-virals and immunopotentiators |
| DE10306250A1 (de) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| PL1638933T3 (pl) | 2003-06-17 | 2008-10-31 | Pfizer | Pochodne n-pirolidyn-3-yloamidu jako inhibitory wychwytu zwrotnego serotoniny i noradrenaliny |
| US7348434B2 (en) * | 2003-08-08 | 2008-03-25 | Antony Bigot | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them |
| BRPI0414909A (pt) * | 2003-10-31 | 2006-11-07 | Otsuka Pharma Co Ltd | composto, agente antituberculoso, e, método para produzir um composto |
| PL1757582T3 (pl) | 2004-05-28 | 2016-04-29 | Mitsubishi Tanabe Pharma Corp | Aryloalkiloaminy i sposób ich wytwarzania |
-
2005
- 2005-10-13 US US11/576,960 patent/US7868014B2/en not_active Expired - Fee Related
- 2005-10-13 JP JP2007536836A patent/JP5188807B2/ja not_active Expired - Fee Related
- 2005-10-13 DE DE602005018381T patent/DE602005018381D1/de not_active Expired - Lifetime
- 2005-10-13 CN CNA200580035313XA patent/CN101094846A/zh active Pending
- 2005-10-13 CA CA002584422A patent/CA2584422A1/en not_active Abandoned
- 2005-10-13 EP EP05804465A patent/EP1805165B1/en not_active Expired - Lifetime
- 2005-10-13 MX MX2007004661A patent/MX2007004661A/es not_active Application Discontinuation
- 2005-10-13 WO PCT/US2005/036665 patent/WO2006044454A1/en not_active Ceased
- 2005-10-13 ES ES05804465T patent/ES2336130T3/es not_active Expired - Lifetime
- 2005-10-13 BR BRPI0516602-0A patent/BRPI0516602A/pt not_active IP Right Cessation
- 2005-10-13 AU AU2005295860A patent/AU2005295860A1/en not_active Abandoned
- 2005-10-13 AT AT05804465T patent/ATE452130T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US7868014B2 (en) | 2011-01-11 |
| DE602005018381D1 (de) | 2010-01-28 |
| WO2006044454A1 (en) | 2006-04-27 |
| JP2008516959A (ja) | 2008-05-22 |
| EP1805165A1 (en) | 2007-07-11 |
| CN101094846A (zh) | 2007-12-26 |
| JP5188807B2 (ja) | 2013-04-24 |
| AU2005295860A1 (en) | 2006-04-27 |
| ATE452130T1 (de) | 2010-01-15 |
| CA2584422A1 (en) | 2006-04-27 |
| ES2336130T3 (es) | 2010-04-08 |
| EP1805165B1 (en) | 2009-12-16 |
| MX2007004661A (es) | 2007-06-22 |
| US20080300266A1 (en) | 2008-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE548374T1 (de) | 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren | |
| EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
| EA200970156A1 (ru) | Пиридизиноновые производные | |
| SG163585A1 (en) | Melanocortin receptor ligands | |
| EA201100311A1 (ru) | Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы | |
| ATE537170T1 (de) | Cgrp-rezeptorantagonisten | |
| WO2008156677A3 (en) | Cyclic peptide melanocortin receptor ligands | |
| MY153915A (en) | Organic compounds | |
| ECSP088623A (es) | Derivados de azepinoindol como agentes farmacéuticos | |
| BRPI0715579A2 (pt) | "composto, composição farmacêutica e uso de um composto" | |
| NO20072435L (no) | CGRP-reseptorantagonister | |
| DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
| EA201070912A1 (ru) | Производные оксима в качестве ингибиторов hsp90 | |
| EA200800321A1 (ru) | Ингибиторы гистондеацетилазы | |
| BRPI0607455A2 (pt) | composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica | |
| SE0303180D0 (sv) | Novel compounds | |
| TW200716584A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| SE0302232D0 (sv) | Novel Compounds | |
| EA201000814A1 (ru) | 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств | |
| CY1108880T1 (el) | Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα | |
| GEP20135959B (en) | Aryl piperazine and their usage as alpha2c antagonists | |
| ATE503755T1 (de) | Cgrp-rezeptorantagonisten | |
| BRPI0516602A (pt) | composto, e, composição farmacêutica | |
| ATE421518T1 (de) | Dihydrochinazolinone als 5ht-modulatoren | |
| ATE507880T1 (de) | Cgrp-rezeptorantagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |